Sharemaestro Newsreel

383,728,970 H Shares of Guangzhou Innogen Pharmaceutical Group Co., Ltd are subject to a Lock-Up Agreement Ending on 14-AUG-2026.

Sisram Medical Sets Final 2025 Dividend and Clarifies 20% Israeli Withholding Tax

Sisram Medical Sets Record Date and Tax Terms for 2025 Final Dividend

Austar Lifesciences Sets Board Meeting to Review Interim Results and Dividend

Guangzhou Innogen Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan

Beijing Health Sets Board Meeting to Approve 2026 Interim Results and Dividend

BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...

This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing …

XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026

SHENZHEN, China, Aug. 12, 2026 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), an innovative research platform company powered by artificial intelligence (AI) and robotics, announced that it will report its interim results for the six months ended June 30, 2026 …

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody …

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co., Ltd. ("Beyang"), an AI-driven innovative …

Hygeia Healthcare Sets Board Meeting to Approve Interim Results and Consider Dividend

Align Technology Prevails in China Patent Infringement Action

Align Technology (ALGN) disclosed late Tuesday that the Jinan Intermediate People's Court in China issued a judgment in its favor, in a patent infringement action against Angelalign Technology's operating subsidiaries in China.The company provides an orthodontic treatment system Silver Upgrade to read this MT …

Align Technology Prevails in China Patent Infringement Action Against Angelalign

SAN JOSE, Calif. & TEMPE, Ariz., August 12, 2026--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a …

Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

The study met its primary and all secondary endpoints at Week 24 Rapid onset of clinical activity was observed with significant improvements as early as Week 4 Durable clinical activity demonstrated following single-dose administration, supporting 6- month dosing for the treatment of CRSwNP '512 …

Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading

Asian equities traded in the US as American depositary receipts were edging slightly lower Tuesday morning, declining 0.14% to 3,020.40 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by diagnostic imaging centers company Concord Medical Services (CCM) and Silver …

Yidu Tech Unit Wins RMB8.6 Million Hospital IT Infrastructure Contract

Town Health shifts Bermuda registered office while maintaining Hong Kong share registrar

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab …

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

Zai Lab Limited reported second-quarter 2026 results showing revenue of US$106.31 million versus US$109.98 million a year earlier, with net loss widening to US$50.83 million from US$40.73 million and basic loss per share increasing to US$0.50 from US$0.40. Over the first half of 2026, …

Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China

Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® …

Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?

Zai Lab (ZLAB) Rebounds Following Earnings While Its Undervalued Narrative Faces A Fresh Test

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Zai Lab (ZLAB) stock is in focus after the company reported second quarter 2026 …

ETFs Investing in Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Stocks

Raily Aesthetic Medicine Issues Positive Profit Alert with Revenue and Profit Turnaround for H1 202612

Raily Aesthetic Medicine Shifts Hong Kong Principal Office to Tsim Sha Tsui

Raily Aesthetic Medicine Signals Interim Profit on Strong Aesthetic Services and Equipment Sales

Qyuns Therapeutics Sets Board Meeting to Approve 2026 Interim Results

Yidu Tech Inc. (2158.HK) stock price, news, quote and history

China Health Group Calls AGM to Renew Board Mandates and Seek New Share-Issuance Authority

Sisram Medical Sets August Board Meeting to Approve Interim Results and Consider Dividend

Sisram Medical to Announce 2026 Interim Results on Wednesday, August 19, 2026

Price to earnings forward of China Health Group Ltd – HKEX:673

Sisram Medical Flags Interim Loss Despite Revenue Growth